论文部分内容阅读
目的探讨吉西他滨联合长春瑞滨和地塞米松治疗复发性非霍奇金淋巴瘤的临床疗效。方法 24例非霍奇金淋巴瘤复发的患者,均应用吉西他滨联合长春瑞滨和地塞米松进行治疗,4周为1个疗程。4个疗程后对24例患者进行12个月的随访,观察患者的总有效率及不良反应发生率。结果 24例患者均完成4个疗程的化疗,且完成随访。完全缓解6例(25.00%),部分缓解10例(41.67%),无变化2例(8.33%),进展6例(25.00%),总有效率为66.67%。白细胞减少的发生率为45.83%,血小板减少的发生率为33.33%,胃肠道反应的发生率为41.67%,肝肾功能损害的发生率为8.33%,贫血的发生率为16.67%。其中白细胞减少及胃肠道反应分别有4例及1例患者为Ⅳ度反应,其余反应均为Ⅲ度以内。结论吉西他滨联合长春瑞滨和地塞米松治疗复发性非霍奇金淋巴瘤有较好的近期疗效,不良反应较低,患者一般可耐受,可在临床中应用。
Objective To investigate the clinical efficacy of gemcitabine combined with vinorelbine and dexamethasone in the treatment of recurrent non-Hodgkin’s lymphoma. Methods Twenty-four non-Hodgkin’s lymphoma patients were treated with gemcitabine combined with vinorelbine and dexamethasone for 4 weeks for one course of treatment. After 4 courses of 24 patients were followed up for 12 months to observe the total effective rate and the incidence of adverse reactions. Results All 24 patients completed 4 cycles of chemotherapy and were followed up. There were 6 cases (25.00%) in complete remission, 10 cases (41.67%) partially relieved, 2 cases (8.33%) unchanged and 6 cases (25.00%) advanced. The total effective rate was 66.67%. The incidence of leukopenia was 45.83%, the incidence of thrombocytopenia was 33.33%, the incidence of gastrointestinal reactions was 41.67%, the incidence of liver and kidney dysfunction was 8.33%, and the incidence of anemia was 16.67%. Including leukopenia and gastrointestinal reactions were 4 cases and 1 case of grade Ⅳ reaction, and the rest were Ⅲ degrees or less. Conclusion Gemcitabine combined with vinorelbine and dexamethasone in the treatment of recurrent non-Hodgkin’s lymphoma has a good short-term efficacy, low adverse reactions, patients are generally tolerable and can be used in clinical practice.